In lung cancer, SPRY4 is a promising target to interdict the progress of NSCLC therapy engaged in the progression of EGFR-mediated ovarian cancer and enhances melanoma cell motility and treatment of gastrointestinal tumors [12, 31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.